Your browser is no longer supported. Please, upgrade your browser.
MYOK MyoKardia, Inc. daily Stock Chart
MYOK [NASD]
MyoKardia, Inc.
Index- P/E- EPS (ttm)-7.12 Insider Own0.20% Shs Outstand49.88M Perf Week0.44%
Market Cap11.84B Forward P/E- EPS next Y-6.66 Insider Trans-40.40% Shs Float49.03M Perf Month71.49%
Income-334.00M PEG- EPS next Q-1.46 Inst Own- Short Float10.86% Perf Quarter133.23%
Sales- P/S- EPS this Y-249.90% Inst Trans2.45% Short Ratio5.06 Perf Half Y246.87%
Book/sh18.22 P/B12.24 EPS next Y-16.60% ROA-55.80% Target Price214.80 Perf Year289.40%
Cash/sh17.28 P/C12.90 EPS next 5Y50.90% ROE-63.10% 52W Range42.65 - 224.00 Perf YTD205.92%
Dividend- P/FCF- EPS past 5Y-52.00% ROI- 52W High-0.46% Beta2.13
Dividend %- Quick Ratio21.00 Sales past 5Y- Gross Margin- 52W Low422.79% ATR4.58
Employees275 Current Ratio21.00 Sales Q/Q- Oper. Margin- RSI (14)89.30 Volatility0.27% 1.23%
OptionableYes Debt/Eq0.00 EPS Q/Q-53.80% Profit Margin- Rel Volume0.51 Prev Close222.14
ShortableYes LT Debt/Eq0.00 EarningsAug 04 AMC Payout- Avg Volume1.05M Price222.97
Recom3.00 SMA2013.78% SMA5052.12% SMA200133.96% Volume540,207 Change0.37%
Sep-20-19Initiated Guggenheim Buy
Oct-01-18Initiated Cantor Fitzgerald Overweight $90
Sep-28-18Initiated Citigroup Buy $90
Sep-10-18Initiated Morgan Stanley Overweight $72
Jul-10-18Initiated BofA/Merrill Buy $71
Jan-18-18Resumed Credit Suisse Outperform $60
Dec-12-17Initiated JP Morgan Overweight $54
Sep-19-17Reiterated Credit Suisse Outperform $45 → $55
Dec-04-15Initiated Wells Fargo Outperform
Nov-23-15Initiated Wedbush Outperform $22
Nov-23-15Initiated Credit Suisse Outperform $18
Oct-24-20 02:10PM  
Oct-23-20 04:44PM  
Oct-22-20 08:37PM  
05:00PM  
Oct-21-20 10:20PM  
04:17PM  
11:47AM  
08:30AM  
Oct-20-20 06:00PM  
03:12PM  
Oct-19-20 03:14PM  
Oct-17-20 02:05PM  
Oct-16-20 08:15PM  
Oct-15-20 04:45PM  
12:15PM  
Oct-14-20 06:52PM  
Oct-13-20 08:20PM  
09:45AM  
Oct-12-20 08:00AM  
Oct-09-20 02:24PM  
10:50AM  
10:44AM  
09:31AM  
08:01AM  
Oct-08-20 04:13PM  
04:11PM  
Oct-07-20 06:30PM  
01:45PM  
12:57PM  
10:39AM  
07:43AM  
Oct-06-20 06:50PM  
03:52PM  
02:58PM  
01:28PM  
12:53PM  
10:21AM  
10:13AM  
Oct-05-20 04:26PM  
01:26PM  
01:22PM  
12:38PM  
11:46AM  
11:41AM  
11:27AM  
10:45AM  
10:24AM  
10:20AM  
09:58AM  
09:35AM  
09:23AM  
09:15AM  
09:11AM  
08:25AM  
07:20AM  
06:49AM  
06:40AM  
06:30AM  
06:29AM  
Sep-09-20 08:00AM  
Sep-08-20 09:52AM  
Sep-02-20 08:00AM  
Aug-29-20 09:30AM  
Aug-11-20 07:35AM  
Aug-10-20 04:05PM  
Aug-05-20 04:05PM  
07:01AM  
Aug-04-20 04:05PM  
Aug-03-20 09:52AM  
08:30AM  
Jul-28-20 08:00AM  
Jul-23-20 04:05PM  
Jul-21-20 07:30AM  
Jul-13-20 05:03PM  
Jul-06-20 08:00AM  
Jun-22-20 08:00AM  
Jun-19-20 08:30AM  
Jun-16-20 08:00AM  
Jun-05-20 11:48AM  
Jun-02-20 11:54PM  
May-16-20 06:51AM  
May-12-20 09:34PM  
01:43PM  
10:09AM  
May-11-20 04:02PM  
10:50AM  
10:49AM  
10:42AM  
07:30AM  
May-06-20 04:05PM  
Apr-07-20 02:16PM  
08:32AM  
Mar-30-20 10:30AM  
Mar-27-20 10:45AM  
Mar-26-20 08:30AM  
Mar-23-20 08:24AM  
Mar-19-20 04:45PM  
Mar-15-20 09:40AM  
Mar-10-20 01:45PM  
Feb-27-20 04:05PM  
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyopathy. Its preclinical programs include MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation; ACT-1 for the treatment of diastolic dysfunction; and LUS-1 for the treatment of diastolic dysfunction. Myokardia, Inc. was founded in 2012 and is headquartered in Brisbane, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GIANAKAKOS ANASTASIOSPresident and CEOJul 02Sale93.985,000469,90919,122Jul 07 05:39 PM
CRANSTON MARY BDirectorJun 30Option Exercise11.6921,629252,84321,629Jul 01 07:28 PM
CRANSTON MARY BDirectorJun 30Sale96.6021,6292,089,3550Jul 01 07:28 PM
CRANSTON MARY BDirectorJun 29Option Exercise11.693714,337371Jul 01 07:28 PM
CRANSTON MARY BDirectorJun 29Sale98.6837136,6110Jul 01 07:28 PM
GIANAKAKOS ANASTASIOSPresident and CEOJun 02Sale102.845,000514,20824,122Jun 04 04:24 PM
GIANAKAKOS ANASTASIOSPresident and CEOMay 18Sale125.0010,0001,250,00029,122May 20 04:55 PM
GIANAKAKOS ANASTASIOSPresident and CEOMay 11Sale101.8625,0002,546,47739,122May 13 05:15 PM
GIANAKAKOS ANASTASIOSPresident and CEOMay 04Sale58.485,000292,38774,122May 06 07:07 PM
GIANAKAKOS ANASTASIOSPresident and CEOApr 30Option Exercise1.5111,50017,328289,582May 04 05:34 PM
GIANAKAKOS ANASTASIOSPresident and CEOApr 16Sale55.001,00055,00076,796Apr 20 06:10 PM
GIANAKAKOS ANASTASIOSPresident and CEOApr 08Sale50.001,50075,00077,796Apr 10 06:27 PM
Harris Taylor C.Chief Financial OfficerApr 06Sale46.991,30561,3227,438Apr 07 05:42 PM
GIANAKAKOS ANASTASIOSPresident and CEOApr 02Sale44.772,500111,91779,296Apr 06 04:06 PM
GIANAKAKOS ANASTASIOSPresident and CEOMar 02Sale64.455,000322,24681,796Mar 04 05:42 PM
GIANAKAKOS ANASTASIOSPresident and CEOFeb 03Sale69.365,000346,82186,777Feb 05 08:22 PM
Fairey WilliamSee RemarksFeb 01Sale68.042,899197,2485,226Feb 03 08:55 PM
GIANAKAKOS ANASTASIOSPresident and CEOJan 14Sale75.395,000376,96591,777Jan 14 08:26 PM
McDowell Robert ScottChief Scientific OfficerJan 06Sale68.452,650181,3955,383Jan 07 07:39 PM
GIANAKAKOS ANASTASIOSPresident and CEOJan 06Sale68.4512,687868,43996,777Jan 07 07:39 PM
Harris Taylor C.Chief Financial OfficerJan 06Sale68.451,683115,2034,993Jan 07 07:39 PM
LADD CYNTHIA JGeneral CounselJan 06Sale68.451,849126,5662,851Jan 07 07:36 PM
Bauer JakeChief Business OfficerJan 06Sale68.452,466168,80057,491Jan 07 05:15 PM
Bauer JakeChief Business OfficerJan 03Option Exercise1.5110,00015,10059,957Jan 07 05:15 PM
GIANAKAKOS ANASTASIOSPresident and CEOJan 03Sale71.805,000359,008109,464Jan 03 08:18 PM
Bauer JakeChief Business OfficerDec 20Option Exercise11.1517,500195,05062,498Dec 23 09:07 PM
Bauer JakeChief Business OfficerDec 20Sale70.0718,9161,325,42143,582Dec 23 09:07 PM
GIANAKAKOS ANASTASIOSPresident and CEODec 02Sale65.025,000325,09886,514Dec 04 04:26 PM
Bauer JakeChief Business OfficerNov 29Sale65.608,136533,71144,998Dec 02 04:10 PM
Bauer JakeChief Business OfficerNov 27Sale65.1313,096852,97753,134Dec 02 04:10 PM
GIANAKAKOS ANASTASIOSPresident and CEONov 04Sale59.075,000295,36591,514Nov 06 06:33 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.